Comparing DNIB Unwind (BIND) and Its Peers
DNIB Unwind (NASDAQ: BIND) is one of 93 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare DNIB Unwind to similar companies based on the strength of its earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and risk.
Risk and Volatility
DNIB Unwind has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500. Comparatively, DNIB Unwind’s peers have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
This table compares DNIB Unwind and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DNIB Unwind Competitors||-917.30%||-187.05%||-24.43%|
Insider & Institutional Ownership
20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 20.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for DNIB Unwind and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DNIB Unwind Competitors||164||544||1200||16||2.56|
As a group, “Biotechnology” companies have a potential upside of 53.39%. Given DNIB Unwind’s peers higher possible upside, analysts clearly believe DNIB Unwind has less favorable growth aspects than its peers.
Valuation & Earnings
This table compares DNIB Unwind and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|DNIB Unwind Competitors||$223.74 million||$57.84 million||-0.73|
DNIB Unwind’s peers have higher revenue and earnings than DNIB Unwind. DNIB Unwind is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
DNIB Unwind peers beat DNIB Unwind on 6 of the 8 factors compared.
About DNIB Unwind
DNIB Unwind, Inc., formerly BIND Therapeutics, Inc. is a shell company. The Company was engaged in developing targeted therapeutics, primarily for the treatment of cancer. As of August 1, 2016, the Company sold all of its assets. The Company’s subsidiaries include BIND (RUS) LLC and DNIB Subsidiary Corporation.
Receive News & Ratings for DNIB Unwind Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DNIB Unwind Inc and related companies with MarketBeat.com's FREE daily email newsletter.